Isabella Ciccone, MPH

Sharon Hesterlee, PhD, chief research officer, Muscular Dystrophy Association, discussed the events that happened in September for National Muscular Dystrophy Awareness Month.

Mark Richardson, MD, PhD, spoke about the successes of thalamic neuromodulation for patients with generalized epilepsy in his presentation at the 2022 Congress of Neurological Surgeons.

A cross-sectional study showed that retinal measurements in patients with “potential” neuromyelitis optica spectrum disorder were similar to those with definite neuromyelitis optica spectrum disorder.

Tabby Khan, MD, MPH, spoke on the impact that the COVID-19 has had on patients with Alzheimer disease and how telehealth has helped with providing care for those patients during a pandemic.

A report on two patients with late-onset neutropenia resulted in an uncommon adverse event following anti-CD20 therapies.

A study conducted via telemonitoring showed that hospital workers who performed night shifts had significant negative impacts on their sleep quality and circadian rhythms.

A survey based on young adult college students indicated that symptoms of insomnia might buffer the association with the acute physiological effects of alcohol, in part because it may heighten the sensitivity to alcohol.

Data from a systemic review suggests that the COVID-19 pandemic is associated with increased rates of subthreshold insomnia symptoms, but not with moderate or severe insomnia, among the global population.

New data from the NOVA trial showed differences in the number of T2 lesions in patients with relapsing-remitting multiple sclerosis at 72 weeks of treatment with natalizumab (Tysabri; Biogen), though seemingly driven by data from only 2 participants with extreme new or newly enlarging T2 hyperintense lesion numbers.

A study using patient data from John Hopkins showed that rituximab treatment was associated with reduced annualized relapse rates in AQP4-IgG seropositive NMOSD and MOGAD.

The TRACK-TBI cohort study revealed that patients with traumatic brain injury and a GCS score of 3 to 12 had a significant increase in the accuracy of prognostic accuracy of IMPACT models.

Data from a MSbase registry on patients with multiple sclerosis show in its findings that the incorporation of the Multiple Sclerosis Severity Score improved the prediction accuracy of relapses in MS.

Findings from a study on Parkinson disease revealed that combining blood biomarkers in addition with clinical measures with prognostics modelling are associated with a more vital prediction in disease progression.

Recent findings from a network meta-analysis suggest that high flow oxygen is more efficacious when compared with low flow oxygen for headache relief.

A narrative review revealed that cluster headache trials have been limited thus far, and that future trials should include novel outcome measures and adjusted end point timing.

In 2 phase 3 randomized placebo-controlled trials, findings showed that although crenezumab was well tolerated, it did not reduce clinical decline in participants with early Alzheimer disease.

A national survey showed in its findings that NSAIDs alone and dopamine receptor antagonists are used commonly for treating primary headache disorders in Canadian emergency departments.

In a recent phase 2 study, 6-months of ketogenic diet for people with relapsing multiple sclerosis resulted in a significant reduction in weight, fatigue, and depression, and improved quality of life.

In a phase 3 trial, ULTIMATE I and II, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide among participants with relapsing multiple sclerosis.

Danielle Kipnis, MA, of Columbia University, discussed the practice of yoga for people with functional neurological disorders from her research and recommendations for future studies in the field.

With diagnosis rates of Alzheimer disease increasing, Tabby Khan, MD, MPH, spoke to the need to focus on cognitive decline in younger patient populations.

Findings from a nonrandomized controlled trial in the Netherlands suggest that sleep time of hospitalized patients may be significantly improved with nonpharmacologic interventions such as the postponement of morning vital sign checks and medication administration rounds from the night to the day shift.

RESCUE-ALS trial, a phase 2 randomized controlled study, showed that ALS disease progression was significantly reduced with CNM-Au8 Treatment.

In a randomized clinical trial, the application of electroacupuncture treatment for insomnia in patients with depression significantly improved the quality of sleep in comparison with sham acupuncture or the control group.

A questionnaire-based study from Saudi Arabia on sleep quality revealed that sleep-related disorders, such as obstructive sleep apnea, are relatively common in patients with Duchenne muscular dystrophy.

Findings from a cross-sectional survey revealed a significant association between depression and a diagnosis of myotonic dystrophy, and that symptoms impacting quality of life are more common in neuromuscular disorders.

A study on ALS progression suggested that tollgate-related prognostic factors have a stronger effect on the time trajectories of passing ALS tollgates in comparison with standard prognostic factors.

In a randomized controlled trial, results demonstrated that acupuncture is to be efficacious in improving insomnia, quality of life, and affective symptoms for patients with ischemic stroke.

Results from pilot program using a VR-based platform suggest medical trainees may benefit from further VR training to gain a complete baseline knowledge of treating lower limb spasticity with onabotulinumtoxinA.

A nonrandomized pilot study demonstrated high adherence rates and acceptability ratings with tele-yoga breathing in patients with ALS, proving that it is a safe and feasible practice.